Oetzel D, Schraube P, Hensley F, Sroka-Pérez G, Menke M, Flentje M
Department of Clinical Radiology, University of Heidelberg, Germany.
Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):455-60. doi: 10.1016/0360-3016(95)00009-N.
Investigations to study correlations between the estimations of biophysical models in three dimensional (3D) treatment planning and clinical observations are scarce. The development of clinically symptomatic pneumonitis in the radiotherapy of thoracic malignomas was chosen to test the predictive power of Lyman's normal tissue complication probability (NTCP) model for the assessment of side effects for nonuniform irradiation.
In a retrospective analysis individual computed-tomography-based 3D dose distributions of a random sample of 46/20 patients with lung/esophageal cancer were reconstructed. All patients received tumor doses between 50 and 60 Gy in a conventional treatment schedule. Biological isoeffective dose-volume histograms (DVHs) were used for the calculation of complication probabilities after applying Lyman's and Kutcher's DVH-reduction algorithm. Lung dose statistics were performed for single lung (involved ipsilateral and contralateral) and for the lung as a paired organ.
In the lung cancer group, about 20% of the patients (9 out of 46) developed pneumonitis 3-12 (median 7.5) weeks after completion of radiotherapy. For the majority of these lung cancer patients, the involved ipsilateral lung received a much higher dose than the contralateral lung, and the pneumonitis patients had on average a higher lung exposure with a doubling of the predicted complication risk (38% vs. 20%). The lower lung exposure for the esophagus patients resulted in a mean lung dose of 13.2 Gy (lung cancer: 20.5 Gy) averaged over all patients in correlation with an almost zero complication risk and only one observed case of pneumonitis (1 out of 20). To compare the pneumonitis risk estimations with observed complication rates, the patients were ranked into bins of mean ipsilateral lung dose. Particularly, in the bins with the highest patient numbers, a good correlation was achieved. Agreement was not reached for the lung functioning as a paired organ.
Realistic assessments for the prediction of radiation-induced pneumonitis seem to be possible. In this respect, the implementation of DVH-analysis in 3D planning could be a helpful tool for the evaluation of treatment plans.
关于研究三维(3D)治疗计划中生物物理模型估算值与临床观察结果之间相关性的调查很少。本研究选择胸部恶性肿瘤放疗中临床症状性肺炎的发生情况,以测试莱曼正常组织并发症概率(NTCP)模型对非均匀照射副作用评估的预测能力。
在一项回顾性分析中,重建了46/20例肺癌/食管癌患者随机样本基于个体计算机断层扫描的3D剂量分布。所有患者在常规治疗方案中接受的肿瘤剂量为50至60 Gy。应用莱曼和库彻的DVH缩减算法后,使用生物等效剂量体积直方图(DVH)计算并发症概率。对单肺(患侧同侧和对侧)以及作为配对器官的肺进行肺部剂量统计。
在肺癌组中,约20%的患者(46例中的9例)在放疗结束后3至12周(中位时间7.5周)出现肺炎。对于这些肺癌患者中的大多数,患侧同侧肺接受的剂量远高于对侧肺,且肺炎患者的平均肺部照射剂量更高,预测的并发症风险增加一倍(38%对20%)。食管癌患者较低的肺部照射剂量导致所有患者的平均肺部剂量为13.2 Gy(肺癌:20.5 Gy),并发症风险几乎为零,仅观察到1例肺炎(20例中的1例)。为了将肺炎风险估算值与观察到的并发症发生率进行比较,将患者按患侧同侧肺平均剂量进行分组。特别是在患者数量最多的分组中,实现了良好的相关性。对于作为配对器官的肺,未达成一致。
对放射性肺炎的预测进行现实评估似乎是可行的。在这方面,在3D规划中实施DVH分析可能是评估治疗计划的有用工具。